Foundation Medicine Appoints Mia Levy, MD, PhD as Chief Medical Officer
Levy will lead company's efforts to help physicians, patients, and researchers interpret and apply genomic information to support decision making in cancer care and research
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced the appointment of Mia Levy, MD, PhD, as its Chief Medical Officer. Dr. Levy is a practicing medical oncologist specializing in the treatment of breast cancer and a nationally recognized leader in biomedical informatics. She joins Foundation Medicine following an accomplished tenure as Director of the Cancer Center at Rush University Medical Center in Chicago.
Dr. Levy has devoted her career to developing systems to support data-driven decision-making in cancer care and research. She has contributed to more than 90 publications on cancer and led the development of My Cancer Genome, an international knowledge resource for precision medicine that provides accessible information to patients and physicians around cancer-driving mutations, clinical trials, and therapies. She previously served as Associate Professor of Cancer Research, Biomedical Informatics and Medicine at Vanderbilt University, and as the Director of Cancer Clinical Informatics for the Vanderbilt-Ingram Cancer Center. She is a forum member of the National Cancer Policy Forum for the National Academies, and a member of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee.
“Our goal is to empower physicians and patients with the genomic information needed to make informed treatment decisions,” said Brian Alexander, MD, MPH, chief executive officer at Foundation Medicine. “Dr. Levy is uniquely positioned to lead our medical team as they work to make this information both available and indispensable at the point of care. She is an accomplished leader and a compassionate physician, and we are very excited to have her join Foundation Medicine.”
Dr. Levy will lead efforts to deepen the company's unparalleled insight into cancer genomics, generate new data to validate the use of comprehensive genomic profiling in oncology, enhance the utility of its high-quality genomic tests and bring innovative new diagnostic technology to patient care.
“We're entering an exciting new chapter for decision-making in precision oncology as we learn more about the biology of cancer and make those learnings useful for physicians in the clinic,” Levy said. “I'm proud to join Foundation Medicine's team of world-class physicians and scientists, as we advance broader applications of its technology that can help shape treatment plans for more people living with cancer globally.”
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.
Source: Foundation Medicine
Erin Smith, 262-914-2779